Towards Healthcare
North America Next Generation Sequencing Market Expands 21.93% CAGR by 2034

North America Next Generation Sequencing Market Trends, Share and Growth Analysis

Market insights predict, the north america next generation sequencing industry is expected to grow from USD 5.08 billion in 2024 to USD 36.87 billion by 2034, driven by a CAGR of 21.93%. North America is growing due to technological advancements and investments in the biotechnology industry.

Category: Biotechnology Insight Code: 5645 Format: PDF / PPT / Excel

North America Next Generation Sequencing Market Size Growth and Regional Production Analysis

The global North America next generation sequencing market size is calculated at USD 5.08 in 2024, grew to USD 6.19 billion in 2025, and is projected to reach around USD 36.87 billion by 2034. The market is expanding at a CAGR of 21.93% between 2025 and 2034.

North America Next Generation Sequencing Market Size 2024 - 2034

Key Takeaways

  • North America next generation sequencing sector is pushing the market to USD 5.08 billion in 2024.
  • Long-term projections show USD 36.87 billion valuation by 2034.
  • Growth is expected at a steady CAGR of 21.93% in between 2025 to 2034.
  • The market grew from $10.27B in 2024 to $12.51B in 2025 and is set to hit $73.47B by 2034, with a CAGR of 21.74%.
  • The U.S. dominated the North America next generation sequencing market share in 2024.
  • Canada is estimated to grow at a significant rate during the forecast period.
  • By technology, the target sequencing & resequencing segment held the major share of the market in 2024.
  • By technology, the WGS segment is expected to grow at a significant rate during 2025-2034.
  • By product, the consumables segment dominated the market in 2024 and is expected to be the fastest-growing during the forecast period.
  • By application, the oncology segment captured the dominant share of the market in 2024.
  • By application, the consumer genomics segment is anticipated to witness the fastest growth rate in the market during the predicted timeframe.
  • By workflow, the sequencing segment held the largest share of the North America next generation sequencing market in 2024.
  • By workflow, the NGS data analysis segment is expected to be the fastest-growing during 2024-2034.
  • By end-use, the academic research segment dominated the market in 2024.
  • By end-use, the clinical research segment is anticipated to grow at the fastest CAGR during the forecast period.

Key Metrics and Overview

Metric Details
Market Size in 2025 USD 6.19 Billion
Projected Market Size in 2034 USD 36.87 Billion
CAGR (2025 - 2034) 21.93%
Market Segmentation By Technology, By Product, By Application, By Workflow, By End-use, By Region
Top Key Players Agilent Technologies, Inc., ThermoFisher Scientific, Inc., QIAGEN, Illumina, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Pacific Biosciences of California, Inc., 10x Genomics, Inc., PerkinElmer, Inc., Genewiz, Partek Incorporated, Becton, Dickinson and Company (BD), Genomic Health, Inc., Guardant Health, Inc., Personalis, Inc.

Next Generation Sequencing Market Growth

The global next-generation sequencing market is valued at $10.27 billion in 2024, expected to rise to $12.51 billion in 2025, and projected to reach about $73.47 billion by 2034, growing at an impressive annual rate of 21.74% over the decade.

Next Generation Sequencing Market Revenue 2023 - 2024

What is Next Generation Sequencing and its Applications?

A novel technique for DNA and RNA sequencing, as well as variant/mutation identification, is called next-generation sequencing (NGS).  NGS can quickly sequence an entire genome or hundreds of thousands of genes.  Deciphering intricate genomic landscapes, locating functional components in genomes, and comprehending the genetic foundation of characteristics and illnesses have all benefited greatly from it.  In medicine, NGS has significantly advanced individualized therapy and illness diagnostics.  It makes it possible to quickly and thoroughly profile a person's genetic composition.

  • In January 2025, the $1.3 million SAFE (Simple Agreement for Future Equity) round was successfully closed, according to Foresee Genomics, a new next-generation sequencing (NGS) solutions firm that specializes in the small and medium-sized laboratory sector.  This is the last pre-revenue funding campaign the firm will do before starting product sales in the US later this year. (Source - CISION PRWeb)
  • In October 2024, in a series A investment, MiLaboratories raised $10 million to revolutionize genomic research. The company plans to leverage its Series A capital to expand into additional regions and attract top personnel, with a strategic concentration on the United States. (Source - businesswire)

How is AI Transforming the North America Next Generation Sequencing Market?

Two revolutionary innovations that have made great strides in recent decades are artificial intelligence (AI) algorithms and sequencing technology. As more data is handled by the biomedical sector and AI systems are able to better handle biological complexity, the connection between these two fields of study will only grow.   In many different situations, ML and DL approaches have been used to sequence data. Significant advances in data processing and interpretation by AI algorithms have benefited the discipline as a whole in a number of areas, such as monitoring minimum residual illness, classifying disease subtypes, predicting treatment response, and risk assessment and early diagnosis.

Market Dynamics

Driver

Heavy Usage in Diagnostics

The market's growth has been largely attributed to the growing and diverse applications of next-generation sequencing in diagnostics.   As a result of its declining costs, sequencing is now being used more often to diagnose various diseases. A range of test kits and testing services is being introduced by the running firms for a number of applications, such as genetic testing, cancer screening, non-invasive prenatal testing, and more.

Restraint

High Expense of NGS

For both patients and healthcare providers, the cost of NGS procedures, which include sequencing, data processing, and interpretation, is a significant barrier to accessibility. NGS equipment's use in clinical settings is limited by the expense of purchasing and maintaining it, especially in institutions with limited resources.

Opportunity

Are Portable Sequencing Devices the Next Step in Next Generation Sequencing?

The ability to sequence the DNA of any organism and make scientific and therapeutic inferences has proven transformative for public health. Because portable handheld sequencing technologies reduce costs, simplify, and speed up sequencing without requiring big clinical laboratories, they are opening the door for the market's future growth. Thanks to real-time sequencing, scientists and medical professionals may now react to sequencing data instantly. For less than $1,000, portable nanopore-based sequencers can sequence the whole genome.

Segmental Insights

The Target Sequencing & Resequencing Segment Led

By technology, the target sequencing & resequencing segment held the major share of the North America next generation sequencing market in 2024. Targeted sequencing offers a rapid and cost-effective way to identify known and undiscovered changes in certain gene sets or genomic regions. Highly concentrated single-gene sequencing is accurate, fast, and affordable with Sanger sequencing. Resequencing is the most effective and crucial method for identifying sequence changes in clinical diagnosis. It provides researchers with precise and understandable details about the variations they have discovered.

The WGS Segment is Growing Significantly

By technology, the WGS segment is expected to grow at a significant rate in the North America next generation sequencing market during 2025-2034. Whole genome sequencing (WGS) is the preferred method for both the identification of actionable cancer drivers and the molecular genetic diagnosis of rare and unknown diseases.   Compared to traditional molecular genetic methods, WGS captures most of the genomic variety and eliminates the need for sequential genetic testing.   WGS data may also be reexamined and reinterpreted several times throughout the course of the patient's journey, possibly making them a lifelong companion.

The Consumables Segment Led & Fastest

By product, the consumables segment dominated the North America next generation sequencing market in 2024 and is expected to be the fastest-growing during the forecast period. NGS has become a useful technique for gaining a more thorough and precise look into the molecular foundations of certain cancers as genomics-focused pharmacology starts to play a bigger role in cancer treatment. NGS-driven companion diagnostics are often seen as directing therapy selection to maximize patient outcomes in the future, since targeted drugs are quickly emerging as the new gold standard of care for cancer.  The field of cancer may be greatly impacted by the speed, sensitivity, and accuracy benefits that NGS offers over conventional techniques.

The Oncology Segment Held the Major Share

By application, the oncology segment captured the dominant share of the North America next generation sequencing market in 2024. NGS has become a useful technique for gaining a more thorough and precise look into the molecular foundations of certain cancers as genomics-focused pharmacology starts to play a bigger role in cancer treatment. NGS-driven companion diagnostics are often seen as directing therapy selection to maximize patient outcomes in the future, since targeted drugs are quickly emerging as the new gold standard of care for cancer.  The field of cancer may be greatly impacted by the speed, sensitivity, and accuracy benefits that NGS offers over conventional techniques.

The Consumer Genomics Segment: Fastest Growth

By application, the consumer genomics segment is anticipated to witness the fastest growth rate in the North America next generation sequencing market during the predicted timeframe. As more individuals buy direct-to-consumer (DTC) genomic tests, the number of people receiving genetic testing outside of the traditional medical paradigm may surpass that of those receiving it. This suggests that doctors and health institutions need to be ready to assist people in understanding the results of genetic testing that is done directly to consumers. Every consumer has a different experience with DTC genetic testing. Thus, a more customized method of providing findings could be required.

The Sequencing Segment Led in 2024

By workflow, the sequencing segment held the largest share of the North America next generation sequencing market in 2024. The science of genomics has undergone a revolution thanks to the fast development of next-generation sequencing (NGS) technologies over the past 20 years, which have also made sequencing available for several clinical and scientific applications. Although the present NGS industry is dominated by typical short-read sequencing technologies, single-cell, long-read, and direct-read sequencing have been made possible by more recent third-generation devices.

The NGS Data Analysis Segment: Fastest Growth

By workflow, the NGS data analysis segment is expected to be the fastest-growing in the North America next generation sequencing market during 2024-2034. Understanding the various NGS data file types in-depth is necessary for effective NGS data analysis.   There are many different ways to analyze NGS data. These include using cloud-based one-click analysis systems like BaseSpace or using command-line tools like BWA, STAR, Bowtie, or samtools directly on your local computers. Many NGS data analysis tools come with comprehensive guides, documentation, and best practices guidelines.

The Academic Research Segment Dominated

By end-use, the academic research segment dominated the North America next generation sequencing market in 2024. With recent technological breakthroughs (NGS), the cost per genome has significantly dropped, making genomic data more accessible to independent researchers. Because genomic analysis is getting cheaper, it is becoming a more desirable and necessary part of every successful bioscience research endeavor. In addition to working on local and international genome projects, the Next Generation Genomics Facility (NGGF) provides genomics services to scientists and teaches researchers.

The Clinical Research Segment: Fastest CAGR

By end-use, the clinical research segment is anticipated to grow at the fastest CAGR in the North America next generation sequencing market during the forecast period. NGS is one of the key technologies that has transformed the molecular and diagnostic domains of pharmacogenomics. Researchers may provide thorough descriptions of genomic landscapes and fill up the gaps in missing data with NGS technology, which helps clinical trials collect as much information as possible regarding the medication.

What are the North America Next Generation Sequencing Market Growth Factors in North America?

North America dominated the North America next generation sequencing market in 2024. because of its advanced healthcare system, significant government funding, and extensive research and development. This domination encourages innovation and early adoption, which drives market growth and attracts important players and investments.   Prominent genomics companies and research facilities drive market expansion and shape trends that impact global market dynamics.

The U.S. North America Next Generation Sequencing Market Trends

One of the biggest and most diverse countries in the world, the U.S. is home to a wide range of people from many cultures and languages. The healthcare and genomics landscape in the United States is as diverse and expansive as the country itself.   Numerous internationally renowned research facilities, notable genomics initiatives, and influential individuals call the U.S. home. As the country's population continues to rise, the already massive U.S. healthcare industry continues to expand.   The Centers for Medicare and Medicaid Services estimate that by 2028, the U.S. will spend an incredible $6.2 trillion on healthcare.

The Canada North America Next Generation Sequencing Market Trends

Leading the genomics revolution are Canadian researchers, companies, and organizations, who are releasing the science's potential to advance industrial innovation, solve global issues, and enhance people's quality of life.    The genomics revolution, for example, is being led by Canadian scientists, companies, and organizations, who are releasing the science's potential to enhance commercial innovation, solve global issues, and enhance people's quality of life.    In order to treat cancer, chronic illnesses, and uncommon diseases, it will encourage the development of customized medicine, cutting-edge diagnostics, and innovative treatments, such as next-generation vaccinations.

Top Companies in the North America Next Generation Sequencing Market

North America Next Generation Sequencing  Market Companies

Latest Announcements by Industry Leaders

In March 2024, according to Madhuri Hegde, PhD, FACMG, SVP and chief scientific officer at Revvity, the company's new process aims to improve the customer experience by utilizing a comprehensive variant library for newborn sequencing research and offering essential components required to go from sample to result.  By tackling the common issues that labs encounter, we are expediting the democratization of genomic sequencing. (Source - revvity)

Recent Developments in the North America Next Generation Sequencing Market

  • In February 2025, DNAstack, a Canadian bioinformatics business, created the Canadian Platform for AI in Health, a cooperative for improving patient outcomes via the development of national and international AI infrastructure for genomes and health. (Source - genomeweb)
  • In October 2024, Illumina, a global pioneer in DNA sequencing and array-based technologies, unveiled the MiSeq i100 Series of sequencing instruments. In order to improve next-generation sequencing (NGS) capabilities for laboratories, the new technologies aim to provide rapid turnaround and ease of use. (Source - EXPRESS HEALTHCARE)

Segments Covered in the Report

By Technology

  • Targeted Sequencing & Resequencing
    • DNA-based
    • RNA-based
  • WGS
  • Whole Exome Sequencing
  • Others

By Product

  • Consumables
    • Sample Preparation
    • Target Enrichment
    • Others
  • Platform
    • Sequencing
    • Data Analysis

By Application

  • Oncology
    • Diagnostics and Screening
      • Oncology Screening
        • Sporadic Cancer
        • Inherited Cancer
      • Companion Diagnostics
      • Other Diagnostics
    • Research Studies
  • Consumer Genomics
  • Clinical Investigation
    • Infectious Diseases
    • Inherited Diseases
    • Idiopathic Diseases
    • Non-Communicable/Other Diseases
  • Reproductive Health
    • NIPT
      • Aneuploidy
      • Microdeletions
    • PGT
    • Newborn Genetic Screening
    • Single Gene Analysis
  • HLA Typing/Immune System Monitoring
  • Metagenomics, Epidemiology & Drug Development
  • Agrigenomics & Forensics

By Workflow

  • Sequencing
  • NGS Data Analysis
    • NGS Primary Data Analysis
    • NGS Secondary Data Analysis
    • NGS Tertiary Data Analysis
  • Pre-Sequencing
    • NGS Library Preparation Kits
    • Semi-automated Library Preparation
    • Automated Library Preparation

By End-use

  • Academic Research
  • Clinical Research
  • Hospitals & Clinics
  • Pharma & Biotech Entities
  • Other Users

By Region

  • North America
    • U.S.
    • Canada

  • Last Updated: 27 May 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

Meet the Team

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and strategy.

Learn more about Shivani Zoting

Aditi Shivarkar, with over 14 years of experience in consumer goods, leads research at Towards Consumer Goods, ensuring precise, actionable insights on trends, consumer preferences, and sustainable packaging for businesses.

Learn more about Aditi Shivarkar

Related Reports

FAQ's

A number of NGS techniques have been developed, such as pyrosequencing, Ion Torrent sequencing, sequencing by synthesis (SBS – Illumina), and sequencing by ligation (SOLiD).

Commoditization is becoming more likely for NGS in the future.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.